Statement of Need: Rationally designed target-based therapies beyond those targeting the estrogen receptor are increasingly important in breast cancer treatments.
Trastuzumab has established itself in HER2+ breast cancer, and its use in the adjuvant and neoadjuvant settings is currently being assessed.
Other novel agents that target other ErbB receptors include the small-molecule epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib; these agents are now being evaluated in breast cancer.
Targeted therapies against the vascular endothelial growth factor (VEGF) pathway, such as bevacizumab and lapatinib, are effective in other malignancies and are also entering the breast cancer arena.
Additional agents target downstream signaling molecules that modulate progression through the cell cycle and resistance to apoptosis, including the mTOR inhibitor RAD001.
This program will provide physicians with an overview of the most recent advances in the field of targeted therapeutics for the treatment of breast cancer.
Compare the efficacy and safety of various estrogen receptor–targeted therapies.
Compare and contrast signal transduction inhibitors currently under evaluation for treatment of breast cancer.
Discuss the efficacy of HER-targeted inhibitors under investigation for the treatment of breast cancer, and relate the current status of trastuzumab-based clinical trials.
Evaluate the efficacy and safety of novel agents designed to restore the apoptotic pathway in tumor cells for treatment of your patients with breast cancer.
Evaluate recent clinical data on the use of angiogenesis inhibitors—alone and in combination regimens—in the treatment of breast cancer.
Who Should Attend: This activity is intended for medical oncologists and other physicians interested in the treatment of breast cancer.
Conference Agenda: Please see www.thecbce.com/currentactivities.asp for the current agenda.
Registration Information: * A limited number of Scholarships are available for fellows. For consideration and further information, please contact Zack Lentz. REGISTRATION FEES: The registration fee covers participation at all conference sessions, meeting materials, and food functions per the agenda.
Physician (in practice or academic research): $395
Fellow, nurse, and other health care professionals (in practice or academic research): $195
Industry/All others: $1,895 (This category is defined by the CBCE as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.)
Conference Fees: Please see website for further information
Continuing Education: Yes
Miscellany: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians. The CBCE designates this educational activity for a maximum of 15.75 category 1 credits towards the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. Participants who submit CME Request for Credit and Evaluation Forms will receive their CME certificate 4-6 weeks after the activity.
Oct 21, 2014 - Targeting a cancer cell's heat shock response protein 70 with panobinostat to induce autophagy in the stressed cell, and then introducing an autophagy inhibitor to force the cell to die off, may be an effective novel treatment strategy for breast cancer, according to a Nov. 16 press briefing presented at the American Association for Cancer Research -- National Cancer Institute -- European Organisation for Research and Treatment of Cancer International Conference, "Molecular Targets and Cancer Therapeutics," held from Nov. 15 to 19 in Boston.